Melanie Duran
Family · Albuquerque, NMNPI 1811569841
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 41.6% of the total. Reporting peaked in 2024 at $10,732 and has fallen 73.3% since, to $2,863 in 2025. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $74.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$6K
- Medtronic$2K
- Theracosbio, LLC$2K
- Insulet Corporation$1K
- Novo Nordisk$879
- Lilly USA, LLC$672
- plus $2K from 20 others
What the payments were for
- Consulting fees$3,16421%
- Speaking & faculty fees$2,19015%
- Travel & lodging$3,05320%
- Food & beverage$6,29842%
- Education$410%
- Other$1951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 12 | $6,218 |
| Medtronic | 23 | $2,081 |
| Theracosbio, LLC | 8 | $1,965 |
| Insulet Corporation | 32 | $1,046 |
| Novo Nordisk | 25 | $879 |
| Lilly USA, LLC | 33 | $672 |
| Bayer | 9 | $358 |
| Boehringer Ingelheim | 12 | $308 |
| Dexcom, Inc. | 10 | $264 |
| Abbott | 2 | $195 |
| AbbVie | 12 | $186 |
| BETA Bionics, Inc. | 1 | $142 |
| Tandem Diabetes Care, Inc. | 5 | $122 |
| Averitas Pharma Inc. | 1 | $118 |
| Phathom Pharmaceuticals, Inc. | 1 | $104 |
| Cequr Corporation | 2 | $54 |
| Novartis | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Alkermes, Inc. | 2 | $30 |
| Amgen | 1 | $29 |
| GSK | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Pfizer | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$4,604
- Brenzavvy$1,827
- MINIMED 780G$1,709
- iLet Bionic Pancreas$427
- Kerendia$254
- Omnipod$250
- Ozempic$237
- MOUNJARO$229
- FREESTYLE COPILOT$165
- VRAYLAR$120
- Qutenza$118
- Wegovy$109
- JARDIANCE$108
- VOQUEZNA$104
How this compares
$14,941 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 621 | $670,331 |
| JardianceEmpagliflozin | 500 | $495,655 |
| TrulicityDulaglutide | 298 | $347,035 |
| MounjaroTirzepatide | 272 | $314,534 |
| JanuviaSitagliptin Phosphate | 103 | $86,279 |
| RybelsusSemaglutide | 67 | $77,975 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 64 | $77,957 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 81 | $74,944 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $59,071 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $56,191 |
| ProliaDenosumab | 31 | $52,698 |
| FarxigaDapagliflozin Propanediol | 58 | $50,591 |
| Humalog Kwikpen U-200Insulin Lispro | 27 | $48,814 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 107 | $38,802 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 298 | $35,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $879 | $753,475712 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev, Humalog | $672 | $685,115618 claims |
| Boehringer IngelheimJardiance | $308 | $495,655500 claims |
| AmgenProlia | $29 | $52,69831 claims |
| AstraZenecaFarxiga | $13 | $50,59158 claims |
| AbbVieSynthroid | $186 | $3,53866 claims |
| Sanofi-aventis U.S. LLCLantus | $6,218 | $1,92520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.
Other family in Albuquerque
- Barbara FranklinAlbuquerque$28K
- Irasema LlewellynAlbuquerque$14K
- Charles GallegosAlbuquerque$10K
- Marlyn NewbyAlbuquerque$9K
- Annmarie FoleyAlbuquerque$8K
- Aimee CasarezAlbuquerque$7K
- Rita SuharliAlbuquerque$6K
- Matthew TotterAlbuquerque$6K
- Roberta ChampouillonAlbuquerque$6K
- Genevieve DavisAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.